spacer
home > pmps > summer 2018 > driving digitalisation
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Driving Digitalisation

Pharmaceutical manufacturers are faced with the task of bringing new drugs to market as quickly as possible, without any compromise on quality or patient safety. A key driver of this demand is the time pressure faced in relation to the expiry of patents. Therefore, manufacturers need to move from R&D to production in the shortest possible time with minimum investment. Digitalisation and the adoption of emerging industrial digital technologies are set to play key parts in the delivery of such objectives.

Digitalisation is the technology focus behind Industry 4.0, and the central message about how it can enhance manufacturing and production capabilities is gaining steady traction. Advocates say its data-driven, highly connected world of seamless technology platforms will drive productivity improvements, promote agile production, aid competitiveness, and, ultimately, build business value and boost economic success.

The recent publication of the government-backed Made Smarter Review has set out a clear road map for the wide-scale adoption of emerging industrial digitalisation technologies and articulates how this can have a significant and positive economic impact. This includes a predicted £455 billion boost for the UK’s manufacturing base, an increase in manufacturing sector growth of up to 3% per annum, a net gain of 175,000 jobs, and a reduction of CO2 emissions by 4.5%.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Alwyn Jones has over 20 years’ experience in automation and engineering, working with market-leading companies, supplying systems and solutions into the highly regulated industry sectors. At Siemens, he is Head of Pharmaceutical and Life Sciences and manages the UK and Ireland pharmaceutical and life sciences sector strategy, helping manufacturers bring new and affordable drugs to market in the shortest possible time, without any compromise on quality.
spacer
Alwyn Jones
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

RSSL introduces same-day mycoplasma testing service in UK

Reading Scientific Services Ltd (RSSL), a leading provider of scientific and technical solutions to the global biopharmaceutical, pharmaceutical, and biopharmaceutical sectors, has introduced the United Kingdom’s first same-day mycoplasma testing service for manufacturers of biologic medicines.
More info >>

White Papers

The BioPharmaSpec Approach”: Mass Spectrometry Based Host Cell Protein Identification and Quantitation

BioPharmaSpec

1. Introduction As part of the development of any biopharmaceutical product, the impurities present must be examined, minimized and where possible characterized (1). These impurities fall into two broad categories: product-related impurities (derived specifically from the drug product itself) and process-related impurities (derived from material associated with the production, processing or purification of the sample). Host cell proteins (HCPs) are process-related impurities that require specific analysis due to the multitude of naturally occurring proteins expressed in the production cell line.
More info >>

 
Industry Events

Pharma Packaging and Labelling East Coast 2019

20-21 February 2019, Phildaelphia, USA

Now in its 11th year, Pharma Packaging and Labeling is back to deliver key, actionable insights into very latest regulatory requirements, technological innovations, strategic developments, and how to implement them into your packaging and labeling chain with both maximum efficiency and minimal cost.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement